FDA.reportPublic FDA data

TARTARIC ACID

Substance profile for UNII W4888I119H, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for TARTARIC ACID
Structure render from PubChem CID 444305

Substance Identity#

UNII
W4888I119H
Preferred term
TARTARIC ACID
Registry number
87-69-4
EC number
201-766-0
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C4H6O6
Chemical structure for TARTARIC ACID
Structure render from PubChem CID 444305

Chemical And Database Identifiers#

InChIKey
FEWJPZIEWOKRBE-JCYAYHJZSA-N
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O
RxCUI
37578
PubChem
444305
NCIt
C47744
INN ID
0

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound444305pubchem.ncbi.nlm.nih.gov/compound/444305
PubChem InChIKey SearchFEWJPZIEWOKRBE-JCYAYHJZSA-Npubchem.ncbi.nlm.nih.gov/#query=FEWJPZIEWOKRBE-JCYAYHJZSA-N
RxNorm37578mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=37578
NCI ThesaurusC47744ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47744
FDA Substance Registration SystemW4888I119Hprecision.fda.gov/uniisearch/srs/unii/W4888I119H
European Community number201-766-0commonchemistry.cas.org/results?q=201-766-0

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
INACTIVE INGREDIENTPainKoolers Topical Analgesic Patch2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use DURLAZA ™ safely and effectively. See full prescribing information for DURLAZA. DURLAZA (aspirin) Extended Release Capsules, for oral use Initial U.S. Approval:20156
ACTIVE MOIETYBicaruvas Double Action Antacid1
ACTIVE INGREDIENTBicaruvas Double Action Antacid1
INACTIVE INGREDIENTDrug Facts2
ACTIVE MOIETYDRUG FACTS:1
ACTIVE INGREDIENTDRUG FACTS:1
ACTIVE MOIETYBicaruvas Double Action Antacid4
ACTIVE INGREDIENTBicaruvas Double Action Antacid4
INACTIVE INGREDIENTDrug Facts8
INACTIVE INGREDIENTDrug Facts7
INACTIVE INGREDIENT70015427 Diethylpropion HCl USP CIV Immediate-Release 25 mg Tablets Diethylpropion HCl USP CIV Controlled-Release 75 mg Tablets2
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTcold & hot patch1
INACTIVE INGREDIENTAvalin External Analgesic Patch1
INACTIVE INGREDIENTAlivio Medicated Pain Patch1
INACTIVE INGREDIENT33f43bcc-72ca-4e32-8885-14a00ccf80101
INACTIVE INGREDIENTf7a550a0-1c0d-40df-b7e6-734ac4f999f33
INACTIVE INGREDIENT51d95206-0f03-4990-b48c-ee0260b051e01
ACTIVE MOIETYAller-Chord F1
ACTIVE INGREDIENTAller-Chord F1
INACTIVE INGREDIENTcold& hot patch1
INACTIVE INGREDIENTSenokotXTRA (standardized senna concentrate)2
INACTIVE INGREDIENTDiethylpropion HCl USP CIV 25 mg Tablets1
INACTIVE INGREDIENTDiethylpropion Hydrochloride Extended Release Tablets, 75 mg CIV Rx only1
INACTIVE INGREDIENTMenthol 5% (Topical Analgesic)3
INACTIVE INGREDIENT5bb28ba7-ba45-4826-92e3-60ea46096ae52
INACTIVE INGREDIENTMenthol 5% (Topical Analgesic)5
INACTIVE INGREDIENTMenthol 5% (Topical Analgesic)4
INACTIVE INGREDIENTMenthol 5% (Topical Analgesic)17
INACTIVE INGREDIENTba11070e-1a36-4d5d-9e48-c37b4e90c0377
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Zolpidem Tartrate safely and effectively. See full prescribing information for Zolpidem Tartrate. Zolpidem Tartrate (Zolpidem Tartrate) TABLET, FILM COATED, EXTENDED RELEASE for ORAL use. Initial U.S. Approval: 19921
INACTIVE INGREDIENTDrug Facts4
INACTIVE INGREDIENTDrug Facts4
INACTIVE INGREDIENTDrug Facts3
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Listing1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTErgotamine Tartrate and Caffeine2
INACTIVE INGREDIENTDrug Facts5
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTSenna Plus8
INACTIVE INGREDIENT1ec47c1b-d9f8-4939-9cd6-9aa6b7f03a9f2
INACTIVE INGREDIENTDRUG FACTS1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts6
INACTIVE INGREDIENTSenna-S5
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENT85b08f4a-d25a-4786-b700-54dca45095ad2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use FLECTOR® PATCH 1.3% safely and effectively. See full prescribing information for FLECTOR PATCH. FLECTOR PATCH® (diclofenac epolamine patch) 1.3% Initial U.S. Approval: 19881
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Olanzapine safely and effectively. See full prescribing information for Olanzapine. Olanzapine (Olanzapine) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION for INTRAMUSCULAR use. Initial U.S. Approval: 20122
INACTIVE INGREDIENTSenna-S1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Aggrenox Capsules safely and effectively. See full prescribing information for Aggrenox Capsules. AGGRENOX® (aspirin/extended-release dipyridamole) Capsules Initial U.S. Approval: 19992
INACTIVE INGREDIENT70015427 Diethylpropion HCl USP C-IV Immediate-Release 25 mg Tablets Diethylpropion HCl USP C-IV Controlled-Release 75 mg Tablets Rx only Rev. March 20077
INACTIVE INGREDIENTOxybutynin Chloride Extended-Release Tablets USP2
INACTIVE INGREDIENTLeader Maximum Strength Laxative1
INACTIVE INGREDIENTFlector® Patch (diclofenac epolamine topical patch) 1.3%6
INACTIVE INGREDIENTLIDODERM® (Lidocaine Patch 5%)4
INACTIVE INGREDIENTThese highlights do not include all the information needed to use FLECTOR® PATCH 1.3% safely and effectively. See full prescribing information for FLECTOR PATCH. FLECTOR PATCH® (diclofenac epolamine patch) 1.3% Initial U.S. Approval: 19883
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Risperidone safely and effectively. See full prescribing Information for Risperidone Oral Solution USP. Initial U.S. Approval: 19933
INACTIVE INGREDIENTThese highlights do not include all the information needed to use risperidone safely and effectively. See full prescribing information for risperidone. Risperidone Oral Solution USP Initial U.S. Approval: 19939
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Olanzapine for Injection safely and effectively. See full prescribing information for Olanzapine for Injection. Olanzapine for Injection, Powder, For Solution for Intramuscular use Initial U.S. Approval: 19962
INACTIVE INGREDIENTLIDODERM® (Lidocaine Patch 5%)1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTLIDODERM® (Lidocaine Patch 5%)1
INACTIVE INGREDIENTDrug Facts1
INACTIVE INGREDIENTMethylergonovine Maleate Tablets, USP1
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Topotecan Injection safely and effectively. See full prescribing information for Topotecan Injection. Must be diluted before intravenous infusion Initial U.S. Approval: 19961
INACTIVE INGREDIENTThese highlights do not include all the information needed to use TEMODAR safely and effectively. See full prescribing information for TEMODAR. TEMODAR (temozolomide) Capsules TEMODAR (temozolomide) for Injection administered via intravenous infusion Initial U.S. Approval: 19991
INACTIVE INGREDIENTDiethylpropion HCl USP CIV 25 mg Tablets3
INACTIVE INGREDIENTThese highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for oral use Initial U.S. Approval: 20101
INACTIVE INGREDIENTFlector® Patch (diclofenac epolamine topical patch) 1.3%2
INACTIVE INGREDIENT70015427 Diethylpropion HCl USP CIV Immediate-Release 25 mg Tablets Diethylpropion HCl USP CIV Controlled-Release 75 mg Tablets2
INACTIVE INGREDIENTThese highlights do not include all the information needed to use Aggrenox Capsules safely and effectively. See full prescribing information for Aggrenox Capsules. AGGRENOX® (aspirin/extended-release dipyridamole) Capsules Initial U.S. Approval: 19991
INACTIVE INGREDIENTL'BEL CLARIFIQUE DERMO RADIANCE MAINS SPF 151
INACTIVE INGREDIENTSENNA-S Tablets1
INACTIVE INGREDIENTZolpidem Tartrate Extended-Release Tablets These highlights do not include all the information needed to use Zolpidem Tartrate safely and effectively. See full prescribing information for Zolpidem Tartrate. Zolpidem Tartrate (Zolpidem Tartrate) TABLET, FILM COATED, EXTENDED RELEASE for ORAL use. Initial U.S. Approval: 19921
INACTIVE INGREDIENTDiethylpropion HCl USP CIV Immediate-Release 25 mg Tablets Diethylpropion HCl USP CIV Controlled-Release 75 mg Tablets1
INACTIVE INGREDIENT5e46b7e9-e640-4db5-882f-73a5dd2482d21
INACTIVE INGREDIENT5ffefcdc-ebfa-4dc8-b484-719658da9d6d2
INACTIVE INGREDIENTLIDODERM® (Lidocaine Patch 5%)1
INACTIVE INGREDIENTSUCRETS COMPLETE1
INACTIVE INGREDIENTTepanil Ten-Tab, 75 mg, Controlled Release Tablets (Diethylpropion hydrochloride)1
INACTIVE INGREDIENTDipyridamole Injection For Intravenous Injection R x only1
INACTIVE INGREDIENTLIDODERM PATCH [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3335
INACTIVE INGREDIENTFLECTOR (DICLOFENAC EPOLAMINE ) PATCH [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]3142
INACTIVE INGREDIENTFLECTOR (DICLOFENAC EPOLAMINE) PATCH [BRYANT RANCH PREPACK]1000
INACTIVE INGREDIENTLIDOCAINE PATCH [BRYANT RANCH PREPACK]1000
INACTIVE INGREDIENTABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]56
INACTIVE INGREDIENTZYPREXA (OLANZAPINE) TABLET ZYPREXA ZYDIS (OLANZAPINE) TABLET, ORALLY DISINTEGRATING ZYPREXA INTRAMUSCULAR (OLANZAPINE) INJECTION, POWDER, FOR SOLUTION [ELI LILLY AND COMPANY ]45
INACTIVE INGREDIENTOXYBUTYNIN CHLORIDE EXTENDED RELEASE (OXYBUTYNIN CHLORIDE) TABLET, EXTENDED RELEASE [KREMERS URBAN PHARMACEUTICALS INC.]23
INACTIVE INGREDIENTTEMODAR (TEMOZOLOMIDE) CAPSULE TEMODAR (TEMOZOLOMIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MERCK SHARP & DOHME CORP.]22
INACTIVE INGREDIENTTOPOTECAN (TOPOTECAN HYDROCHLORIDE) INJECTION, SOLUTION, CONCENTRATE [HOSPIRA, INC.]16
INACTIVE INGREDIENTRISPERDAL (RISPERIDONE) TABLET RISPERDAL M-TAB (RISPERIDONE) TABLET, ORALLY DISINTEGRATING RISPERDAL (RISPERIDONE) SOLUTION [JANSSEN PHARMACEUTICALS, INC.]15
INACTIVE INGREDIENTRISPERIDONE TABLET, ORALLY DISINTEGRATING [PAR PHARMACEUTICAL COMPANIES, INC.]15
INACTIVE INGREDIENTTEMOZOLOMIDE CAPSULE [SUN PHARMA GLOBAL FZE]15
INACTIVE INGREDIENTDIETHYLPROPION HYDROCHLORIDE ER (DIETHYLPROPION HYDROCHLORIDE) TABLET, EXTENDED RELEASE [PD-RX PHARMACEUTICALS, INC.]12
INACTIVE INGREDIENTLIDOCAINE PATCH [QUALITEST PHARMACEUTICALS]12
INACTIVE INGREDIENTERAXIS (ANIDULAFUNGIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ROERIG]11
INACTIVE INGREDIENTDIETHYLPROPION HYDROCHLORIDE ER (DIETHYLPROPION HYDROCHLORIDE) TABLET, EXTENDED RELEASE [LANNETT COMPANY, INC.]10
INACTIVE INGREDIENTHYCAMTIN (TOPOTECAN HYDROCHLORIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GLAXOSMITHKLINE LLC]10
INACTIVE INGREDIENTRISPERIDONE TABLET RISPERIDONE SOLUTION RISPERIDONE M-TAB (RISPERIDONE) TABLET, ORALLY DISINTEGRATING [JANSSEN PHARMACEUTICAL, INC.]10
INACTIVE INGREDIENTTEMOZOLOMIDE CAPSULE [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC]10
INACTIVE INGREDIENTLIDOCAINE PATCH [ACTAVIS PHARMA, INC.]9
INACTIVE INGREDIENTLIDODERM (LIDOCAINE) PATCH [ENDO PHARMACEUTICALS INC.]9
INACTIVE INGREDIENTICY HOT ARM NECK LEG AND SMALL AREAS (MENTHOL) PATCH ICY HOT BACK AND LARGE AREAS (MENTHOL) PATCH ICY HOT XL BACK AND LARGE AREAS (MENTHOL) PATCH [CHATTEM, INC.]8
INACTIVE INGREDIENTZOLPIDEM TARTRATE TABLET, FILM COATED, EXTENDED RELEASE [ACTAVIS PHARMA, INC.]8
INACTIVE INGREDIENTDOLOR-PARCHE WITH LIDOCAINE-RX (CAPSAICIN, LIDOCAINE, MENTHOL, AND METHYL SALICYLATE) PATCH [TWO HIP CONSULTING, LLC]7
INACTIVE INGREDIENTLIDODERM (LIDOCAINE) PATCH [BRYANT RANCH PREPACK]7

Inactive Ingredient Database#

Browse recovered IID releases and source provenance.

Current IID rows for UNII W4888I119H page 1 of 1 · 24 matching rows.

Ingredient, UNII, CAS table
IngredientUNIICASDosage formRoutePotencyMaximum daily exposure
TARTARIC ACIDW4888I119H526830INJECTIONINTRAMUSCULAR11 mg
TARTARIC ACIDW4888I119H526830INJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONINTRAMUSCULAR11 mg
TARTARIC ACIDW4888I119H526830INJECTION, SOLUTIONINTRAMUSCULAR18 mg
TARTARIC ACIDW4888I119H526830INJECTIONINTRAVENOUS20 mg
TARTARIC ACIDW4888I119H526830INJECTION, POWDER, FOR SOLUTIONINTRAVENOUS20 mg
TARTARIC ACIDW4888I119H526830INJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONINTRAVENOUS20 mg
TARTARIC ACIDW4888I119H526830INJECTION, SOLUTIONINTRAVENOUS20 mg
TARTARIC ACIDW4888I119H526830SOLUTION, CONCENTRATEINTRAVENOUS20 mg
TARTARIC ACIDW4888I119H526830CAPSULEORAL400 mg
TARTARIC ACIDW4888I119H526830CAPSULE, EXTENDED RELEASEORAL1325 mg
TARTARIC ACIDW4888I119H526830PELLETORAL354 mg
TARTARIC ACIDW4888I119H526830POWDER, FOR SOLUTIONORAL270 mg
TARTARIC ACIDW4888I119H526830SOLUTIONORAL270 mg
TARTARIC ACIDW4888I119H526830SUSPENSIONORAL40 mg
TARTARIC ACIDW4888I119H526830TABLETORAL63 mg
TARTARIC ACIDW4888I119H526830TABLET, COATEDORAL10 mg
TARTARIC ACIDW4888I119H526830TABLET, EXTENDED RELEASEORAL96 mg
TARTARIC ACIDW4888I119H526830TABLET, FILM COATEDORAL30 mg
TARTARIC ACIDW4888I119H526830TABLET, FOR SUSPENSIONORAL28 mg
TARTARIC ACIDW4888I119H526830TABLET, ORALLY DISINTEGRATINGORAL45 mg
TARTARIC ACIDW4888I119H133379SUPPOSITORYRECTAL43 mg
TARTARIC ACIDW4888I119H526830INJECTION, SOLUTIONSUBCUTANEOUS18 mg
TARTARIC ACIDW4888I119H133379TABLETSUBLINGUALNA
TARTARIC ACIDW4888I119H526830SYSTEMTOPICAL349 mg